Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Public ClinicalTrials.gov record NCT07022483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Study identification
- NCT ID
- NCT07022483
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 710 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2025
- Primary completion
- Mar 22, 2032
- Completion
- Mar 22, 2032
- Last update posted
- Jul 27, 2026
2025 – 2032
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Broward Health Medical Center | Fort Lauderdale | Florida | 33316 | Recruiting |
| Miami Cancer Institute | Miami | Florida | 33176 | Recruiting |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | Recruiting |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | Recruiting |
| Trials365 LLC | Shreveport | Louisiana | 71103 | Recruiting |
| FirstHealth of the Carolinas, Inc. | Pinehurst | North Carolina | 28374 | Recruiting |
| University of Cincinnati Physicians Group, LLC | Cincinnati | Ohio | 45206 | Recruiting |
| Avera Medical Group Gynecologic Oncology Sioux Falls | Sioux Falls | South Dakota | 57105 | Recruiting |
| Texas Oncology, P.A. - Tyler | Sioux Falls | South Dakota | 57105 | Recruiting |
| Texas Oncology San Antonio Medical Center | San Antonio | Texas | 78240 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07022483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07022483 live on ClinicalTrials.gov.